{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:15:25Z","timestamp":1762460125348,"version":"3.41.2"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"crossref","award":["201369"],"award-info":[{"award-number":["201369"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"crossref"}]},{"name":"SHCS Research Foundation"},{"name":"ViiV Healthcare LLC"},{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005205","name":"Janssen R&D","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Bristol-Myers Squibb"},{"name":"Merck Sharp & Dohme Corp"},{"name":"Gilead Sciences, and the European Union\u2019s Seventh Framework Programme"},{"DOI":"10.13039\/501100001732","name":"Danish National Research Foundation","doi-asserted-by":"crossref","award":["DNRF126"],"award-info":[{"award-number":["DNRF126"]}],"id":[{"id":"10.13039\/501100001732","id-type":"DOI","asserted-by":"crossref"}]},{"name":"International Cohort Consortium of Infectious Disease"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Several studies have reported suboptimal efficacy of direct-acting antivirals (DAAs) to treat hepatitis C virus (HCV) subtypes endemic to sub-Saharan Africa (SSA) and Southeastern Asia (SEA). The extent of this issue in individuals with human immunodeficiency virus (HIV)\/HCV from SSA or SEA residing in Europe is unknown.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We retrospectively analyzed data from several prospective European cohorts of people living with HIV. We included individuals with HIV\/HCV who originated from SSA or SEA, were treated with interferon-free DAAs, and had an available HCV RNA result \u226512 weeks after the end of treatment. The primary outcome was sustained virological response at least 12 weeks after the end of treatment (SVR12).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 3293 individuals with HIV\/HCV treated with DAA and with available SVR12 data, 142 were from SSA (n = 64) and SEA (n = 78). SVR12 was achieved by 60 (94% [95% confidence interval {CI}, 86%\u201398%]) individuals from SSA and 76 (97% [95% CI, 92%\u201399%]) from SEA. The genotypes of the 6 individuals failing DAA treatment were 2, 3a, 3h, 4a, 4c, and 6j. For 2 of the 4 unsuccessfully treated individuals with available sequence data at treatment failure, NS5A resistance-associated substitutions were present (30R\/93S in an individual with genotype 4c and 31M in an individual with genotype 6j).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>SVR12 rates were high in individuals with HIV\/HCV residing in Europe and originating from regions where intrinsically NS5A-resistant HCV strains are endemic. HCV elimination for this population in Europe is unlikely to be hampered by suboptimal DAA efficacy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofac508","type":"journal-article","created":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T20:15:45Z","timestamp":1664568945000},"source":"Crossref","is-referenced-by-count":2,"title":["Low Risk of Failing Direct-Acting Antivirals in People With Human Immunodeficiency Virus\/Hepatitis C Virus From Sub-Saharan Africa or Southeastern Asia: A European Cross-Sectional Study"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0999-2336","authenticated-orcid":false,"given":"Cas","family":"Isfordink","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Amsterdam Institute for Infection and Immunity, Amsterdam University Medical Center, University of Amsterdam , Amsterdam , The Netherlands"},{"name":"Department of Gastroenterology and Hepatology, University Medical Centre Utrecht , Utrecht , The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9512-8928","authenticated-orcid":false,"given":"Anders","family":"Boyd","sequence":"additional","affiliation":[{"name":"Stichting HIV Monitoring , Amsterdam , The Netherlands"},{"name":"Department of Infectious Diseases, Research and Prevention, Public Health Service of Amsterdam , Amsterdam , The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8316-1122","authenticated-orcid":false,"given":"Amanda","family":"Mocroft","sequence":"additional","affiliation":[{"name":"Centre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, University College London , London , United Kingdom"},{"name":"Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, University of Copenhagen , Copenhagen , Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4638-1940","authenticated-orcid":false,"given":"Katharina","family":"Kusejko","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich , Zurich , Switzerland"},{"name":"Institute of Medical Virology, University of Zurich , Zurich , Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colette","family":"Smit","sequence":"additional","affiliation":[{"name":"Stichting HIV Monitoring , Amsterdam , The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"de Wit","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, St Pierre Hospital, Universit\u00e9 Libre de Bruxelles , Brussels , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tabitha","family":"Mahungu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Royal Free Hospital London NHS Foundation Trust , London , United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolin","family":"Falconer","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases\/Venh\u00e4lsan, S\u00f6dersjukhuset , Stockholm , Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Wandeler","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern , Bern , Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0933-7833","authenticated-orcid":false,"given":"Matthias","family":"Cavassini","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Lausanne University Hospital, University of Lausanne , Lausanne , Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel","family":"St\u00f6ckle","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University of Basel , Basel , Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janke","family":"Schinkel","sequence":"additional","affiliation":[{"name":"Section of Clinical Virology, Department of Medical Microbiology and Infection Prevention, Amsterdam Infection and Immunity Institute, Amsterdam University Medical Center, University of Amsterdam , Amsterdam , The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andri","family":"Rauch","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern , Bern , Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Peters","sequence":"additional","affiliation":[{"name":"Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, University of Copenhagen , Copenhagen , Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"van der Valk","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Amsterdam Institute for Infection and Immunity, Amsterdam University Medical Center, University of Amsterdam , Amsterdam , The Netherlands"},{"name":"Stichting HIV Monitoring , Amsterdam , The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for EuroSIDA, the Swiss HIV Cohort Study, and the ATHENA Observational Cohort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,9,30]]},"reference":[{"key":"2022102620084670000_ofac508-B1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Polaris Observatory HCV Collaborators","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2022102620084670000_ofac508-B2","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.jhep.2019.09.021","article-title":"DAA Failures in African patients with \u201cunusual\u201d HCV subtypes: Hey! Didn\u2019t you know there was another world?","volume":"71","author":"Pawlotsky","year":"2019","journal-title":"J Hepatol"},{"key":"2022102620084670000_ofac508-B3","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jhep.2019.07.025","article-title":"Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: implications for global elimination of hepatitis C","volume":"71","author":"Childs","year":"2019","journal-title":"J Hepatol"},{"key":"2022102620084670000_ofac508-B4","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S2468-1253(20)30086-8","article-title":"Glecaprevir\u2013pibrentasvir to treat chronic hepatitis C virus infection in Asia: 2 multicentre, phase 3 studies\u2014a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2)","volume":"5","author":"Wei","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2022102620084670000_ofac508-B5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S2468-1253(18)30382-0","article-title":"Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir\u2013sofosbuvir (SHARED): a single-arm trial","volume":"4","author":"Gupta","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2022102620084670000_ofac508-B6","doi-asserted-by":"crossref","first-page":"ofab006","DOI":"10.1093\/ofid\/ofab006","article-title":"Direct-acting antiviral treatment for hepatitis C genotypes uncommon in high-income countries: a Dutch nationwide cohort study","volume":"8","author":"Isfordink","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2022102620084670000_ofac508-B7","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S2468-1253(18)30343-1","article-title":"Sofosbuvir\u2013velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial","volume":"4","author":"Wei","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2022102620084670000_ofac508-B8","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C\u2014final update of the series","volume":"73","author":"European Association for the Study of the Liver","year":"2020","journal-title":"J Hepatol"},{"key":"2022102620084670000_ofac508-B9","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S1473-3099(15)00485-5","article-title":"Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis","volume":"16","author":"Platt","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2022102620084670000_ofac508-B10","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1473-3099(15)00006-7","article-title":"Hepatitis C seroprevalence and HIV co-infection in sub-Saharan Africa: a systematic review and meta-analysis","volume":"15","author":"Rao","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2022102620084670000_ofac508-B11","first-page":"69","article-title":"Prevalence and disease burden of HCV coinfection in HIV cohorts in the Asia Pacific region: a systematic review and meta-analysis","volume":"18","author":"Martinello","year":"2016","journal-title":"AIDS Rev"},{"year":"2020","author":"van Sighem","key":"2022102620084670000_ofac508-B12"},{"key":"2022102620084670000_ofac508-B13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/ije\/dyab141","article-title":"Cohort profile update: the Swiss HIV Cohort Study (SHCS)","volume":"51","author":"Scherrer","year":"2021","journal-title":"Int J Epidemiol"},{"key":"2022102620084670000_ofac508-B14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/hiv.12810","article-title":"The EuroSIDA study: 25 years of scientific achievements","volume":"21","author":"Laut","year":"2020","journal-title":"HIV Med"},{"key":"2022102620084670000_ofac508-B15","doi-asserted-by":"crossref","first-page":"e022516","DOI":"10.1136\/bmjopen-2018-022516","article-title":"AIDS Therapy Evaluation in the Netherlands (ATHENA) national observational HIV cohort: cohort profile","volume":"8","author":"Boender","year":"2018","journal-title":"BMJ Open"},{"key":"2022102620084670000_ofac508-B16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAD.0000000000001928","article-title":"Uptake of HCV treatment in HIV\/HCV coinfected patients across Europe in the era of direct-acting antivirals","volume":"32","author":"Peters","year":"2018","journal-title":"AIDS"},{"key":"2022102620084670000_ofac508-B17","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1002\/hep.30342","article-title":"Highly diverse hepatitis C strains detected in sub-Saharan Africa have unknown susceptibility to direct-acting antiviral treatments","volume":"69","author":"Davis","year":"2019","journal-title":"Hepatology"},{"key":"2022102620084670000_ofac508-B18","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1099\/vir.0.011981-0","article-title":"Predominance of hepatitis C virus genotype 4 infection and rapid transmission between 1935 and 1965 in the Central African Republic","volume":"90","author":"Njouom","year":"2009","journal-title":"J Gen Virol"},{"key":"2022102620084670000_ofac508-B19","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jhep.2017.03.014","article-title":"Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses","volume":"67","author":"Welzel","year":"2017","journal-title":"J Hepatol"},{"key":"2022102620084670000_ofac508-B20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/QAI.0000000000002745","article-title":"Discriminating between premigration and postmigration HIV acquisition using surveillance data","volume":"88","author":"Pantazis","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022102620084670000_ofac508-B21","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S2468-1253(21)00399-X","article-title":"Safety and efficacy of sofosbuvir-velpatasvir-voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial","volume":"7","author":"Gupta","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofac508\/46226367\/ofac508.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/10\/ofac508\/46648931\/ofac508.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/10\/ofac508\/46648931\/ofac508.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T20:09:51Z","timestamp":1666814991000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofac508\/6732508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofac508","relation":{},"ISSN":["2328-8957"],"issn-type":[{"type":"electronic","value":"2328-8957"}],"subject":[],"published-other":{"date-parts":[[2022,10,1]]},"published":{"date-parts":[[2022,9,30]]},"article-number":"ofac508"}}